← Back to Clinical Trials
Recruiting NCT06618599

NCT06618599 Mid-transverse Process Combined With Erector Spinae Block Versus Paravertebral Plane Block

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06618599
Status Recruiting
Phase
Sponsor Cairo University
Condition Lung Cancer
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2024-10-01
Primary Completion 2026-05-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Mid-transverse process to pleura block combined with erector spinae blockparavertebral block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2024-10-01 with a primary completion date of 2026-05-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare efficacy of Mid-transverse process to pleura block combined with erector spinae block versus paravertebral plane block in cancer patients undergoing thoracotomy surgeries.

Eligibility Criteria

Inclusion Criteria: * lung cancer patients for thoracotomy surgeries. * Physical status American Society of Anesthesiologists (ASA )II, III. * Age ≥ 18 and ≤ 65 Years. * Body mass index (BMI): \> 20 kg/m2 and \< 35 kg/m2 Exclusion Criteria: * Patient refusal * physical status ASA IV, * Age \<18 years or \>65 years * BMI \< 20 kg/m2 and \>35 kg/m2 * Known sensitivity or contraindication to drug used in the study (local anesthetics, opioids). * History of psychological disorders and/or chronic pain. * Contraindication to regional anesthesia e.g., local sepsis, pre- existing peripheral neuropathies, and coagulopathy. * Severe respiratory, cardiac, hepatic or renal disease.

Contact & Investigator

Central Contact

sayed M abed, MD degree

✉ sydabed2020@outlook.com

📞 +201226806532

Principal Investigator

sayed M Abed

PRINCIPAL INVESTIGATOR

Cairo University

Frequently Asked Questions

Who can join the NCT06618599 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06618599 currently recruiting?

Yes, NCT06618599 is actively recruiting participants. Contact the research team at sydabed2020@outlook.com for enrollment information.

Where is the NCT06618599 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT06618599 clinical trial?

NCT06618599 is sponsored by Cairo University. The principal investigator is sayed M Abed at Cairo University. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology